ImmunoLin Improves Quality of Life in New IBS Study

Ankeny, IA—January 17, 2006--Dr. John Harvey Kellogg—the inventor of the corn flake—believed that 90% of all health problems start in the digestive tract. Researchers from Proliant Health and Biologicals, based here, have observed that symptoms in digestive disorders—typically abdominal cramps and diarrhea—signal inflammation, and are common in immune deficiencies. In a new study using ImmunoLin®—an immunoglobulin protein isolate with immune-enhancing effects, developed by Proliant— company researchers successfully improved quality-of-life and reduced symptoms of Irritable Bowel Syndrome (IBS), one of the most common chronic digestive-tract disorders.

Leading up to the IBS study, Proliant researchers observed that inducing mild inflammation produces changes in gut permeability, a factor in IBS. As permeability increases, more antigens (toxins) enter the gut, triggering the immune reaction and inflammation that cause the pain and diarrhea associated with IBS. The researchers surmised that if they could eliminate foreign antigens—a core function of ImmunoLin—symptoms of IBS would subside.

Researchers recruited 33 females and 18 males—the disorder is more prevalent in women—aged 40 to 55 with diarrhea-predominant IBS. During the six-week double-blind study, subjects randomly received one of three treatments: 10 gm of ImmunoLin, 10 gm of soy protein, or a combination of 5 gm of ImmunoLin and 5 gm of soy protein, in 20 capsules per day taken five at a time. Overall days with symptoms decreased by 16% and 18% in the 5 gm ImmunoLin and 10 gm ImmunoLin groups, respectively, compared to the soy protein control group.

From the 4th through the 6th weeks, overall days with symptoms decreased by 24% in the 10 gm Immunolin group compared to the soy control group. Noting this acceleration in quality-of-life, Proliant lead researcher Eric Weaver, PhD, observed, “We may need to do a longer study because results were improving as the study progressed.” Weaver also noted that ImmunoLin is a lactose-free alternative safe for those IBS sufferers with diarrhea and gas. “People who struggle with IBS often feel they have sensitivity to dairy and animal proteins,” Weaver continued, “and the study shows ImmunoLin is a safe option for them.”

IBS affects between 15 million and 30 million people in the U.S., with up to half of these suffering from the diarrhea-prevalent form. The Proliant study suggests that, with continuous use, IBS sufferers may be able to reduce days with symptoms by one to two months, or more, per year. Researchers expect to publish the study sometime this spring.
Proliant has over 50 studies, conducted by major university researchers, showing ImmunoLin supports the immune response in animals. ImmunoLin is already in use in the professional market through an exclusive arrangement with Xymogen as IgG 2000 DF and ImmunoBar. Several branded natural products companies already use ImmunoLin in their formulations for its immune-enhancing effects, including NOW Foods ImmunAdvantage, Ergo Pharm GF-Pro, Swanson Health Products Swanson Ultra IgG Concentrate, and Schiff ImmunAssure.

* * *

Proliant Health and Biologicals was founded in 1998 to develop bioactive proteins and peptides for the nutraceutical and pharmaceutical markets. For more information, please contact Lori Stevenson, Vice President of Sales, 2425 SE Oak Tree Court, Ankeny, IA, 50021. Telephone: 515-289-7621; fax: 515-289-5821; email: [email protected]; Web site:

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.